Prognostic Role of High Sensitivity Troponin During Follow up in the Evolution of Acute Myocarditis

Who can take part

• Male or female patients over 18 years of age
• Patients hospitalized at Grenoble Alpes University Hospital and Lyon University Hospital between June 2016 and June 2025
• Having presented chest pain and ≥1 diagnostic criteria or if no chest pain, presence of ≥2 diagnostic criteria below :; Electrical abnormalities (supra- or sub-ST, T-wave inversion, atrioventricular blocks 1-3 conduction disorders); Elevation of cardiac biomarkers (troponin); Kinetic abnormalities on cardiac ultrasound
• Associated with ≥2 MRI criteria of tissue abnormality (edema, hyperhemia, myocardial fibrosis)
• Patient affiliated to a social security scheme or beneficiary of such a scheme
• No opposition to participation

Who cannot take part

• Myocarditis secondary to immunotherapy
• Presence of documented coronary artery disease (coronary angiography or cardiac CT)
• Infiltrative heart disease (sarcoidosis or cardiac amyloidosis)
• Severe valve disease
• Cardiac tumor
• Absence of documented coronary artery disease (cardiac CT or coronary angiography) or age <30 and low risk of coronary artery disease
• Presence of cardiomyopathy (hypertrophic cardiomyopathy, dilated cardiomyopathy)
• Takotsubo
• Constrictive or chronic pericarditis
• Loeffler's endocarditis
• Non-compaction of the left ventricle
• Pulmonary embolism
• Coronary spasm
• Patients covered by articles L1121-5 to L1121-8 of the French Public Health Code (pregnant women, parturients, nursing mothers; persons deprived of liberty by judicial or administrative decision; protected adults)